Amiksin 125 mg 6 tablets, film-coated

As part of combination therapy:
For children aged 7 to 18 years:

• treatment of influenza and other acute respiratory viral infections (ARVI).
For adults:

• treatment of influenza and other ARVI;

• treatment of herpes infection.
Prevention of influenza and other ARVI in adults.

Amiksin® is taken orally, after meals.
For children aged 7 to 18 years:
In uncomplicated forms of influenza and other acute respiratory viral infections (ARVI) - 60 mg once daily on the 1st, 2nd, and 4th days from the start of treatment. Total course dose - 180 mg (3 tablets).
For adults:
For the treatment of influenza and other ARVI - 125 mg per day for the first 2 days of treatment, then 125 mg every 48 hours. Total course dose - 750 mg (6 tablets).
For the prevention of influenza and other ARVI - 125 mg once a week for 6 weeks. Total course dose - 750 mg (6 tablets).
For the treatment of herpes infection - 125 mg for the first two days, then 125 mg every 48 hours. Total course dose - 1.25-2.5 g (10-20 tablets).
In the case of persistent symptoms of influenza and other ARVI lasting more than 4 days, consult a doctor.

Composition per tablet
Tilorone - 125.0 mg.
Excipients:
core: potato starch - 46.000 mg; microcrystalline cellulose - 120.000 mg; povidone (povidone K30) - 3.000 mg; calcium stearate - 3.000 mg; croscarmellose (sodium croscarmellose) - 3.000 mg;
coating: hypromellose (hydroxypropylmethylcellulose) - 6.8100 mg; titanium dioxide - 3.5630 mg; macrogol (polyethylene glycol-4000) - 0.9130 mg; polysorbate-80 (Tween-80) - 0.1140 mg; yellow quinoline dye (E 104) - 0.2470 mg; sunset yellow dye (E 110) - 0.3530 mg.

Hypersensitivity to tilorone or any other component of the product. Pregnancy and breastfeeding period. Pediatric age up to 7 years (for the dosage of 60 mg), pediatric age up to 18 years (for the dosage of 125 mg).

Use during pregnancy and breastfeeding
The use of the product during pregnancy is contraindicated. If the use of the product is necessary during lactation, breastfeeding should be discontinued.

Effect on the ability to drive vehicles and operate machinery
The drug does not have a negative impact on the ability to drive vehicles or engage in other potentially hazardous activities that require increased attention and quick psychomotor reactions.

Allergic reactions, dyspeptic phenomena, and transient chills may occur. If any of the side effects listed in the instructions worsen, or if you notice any other side effects not mentioned in the instructions, inform your doctor.

Cases of overdose of the drug are not known.

Compatible with antibiotics and traditional medications for the treatment of viral and bacterial diseases. No clinically significant interaction of Amiksin® with antibiotics and traditional medications for the treatment of viral and bacterial diseases has been identified.

Low-molecular-weight synthetic interferon inducer that stimulates the production of all types of interferons (alpha, beta, gamma, and lambda) in the body. The main producers of interferon in response to the administration of Tilorone are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils, and granulocytes. After oral administration, the peak production of interferon is observed in the sequence of intestine - liver - blood within 4-24 hours. Amiksin® has immunomodulatory and antiviral effects.

According to experimental studies, after a single oral administration of Amiksin® at a dose equivalent to the maximum daily dose for humans, the maximum concentration of lambda interferon in lung tissue is detected after 24 hours, and alpha interferon after 48 hours. The induction of lambda interferon in lung tissue contributes to increased antiviral protection of the respiratory tract during influenza and other respiratory viral infections.

In human leukocytes, it induces the synthesis of interferon. It stimulates bone marrow stem cells, enhances antibody formation depending on the dose, reduces the degree of immunosuppression, and restores the ratio of T-suppressors to T-helpers. It is effective against various viral infections, including influenza viruses, other acute respiratory viral infections, hepatitis viruses, and herpesviruses. The mechanism of antiviral action is associated with the inhibition of translation of virus-specific proteins in infected cells, resulting in the suppression of virus reproduction.

After oral administration, it is rapidly absorbed from the gastrointestinal tract. Bioavailability is 60%. Approximately 80% of the drug binds to plasma proteins. The drug is excreted almost unchanged through the intestines (70%) and through the kidneys (9%). The half-life (T1/2) is 48 hours. The drug is not subject to biotransformation and does not accumulate in the body.